Clinical trial
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients…
NCT00025389 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00025389 |
|---|---|
| Title | Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer |
| Official title | A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | bevacizumab, carboplatin, paclitaxel, conventional surgery, neoadjuvant therapy |
| Enrollment | 8 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: